secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2022-09-20T23:59:59+00:00
Accession:  0001104659-22-101644
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics appoints Matthias Alder as CEO; Eric Richman resigns effective Sept 20, 2022
--------------------------------------------------------------------------------

- Eric Richman resigned as CEO effective Sept 20, 2022; will remain on board through 2023 annual meeting and serve as senior advisor.
- Matthias Alder, formerly COO, appointed President and CEO and to a Board seat; receives $500k base salary, 50% target bonus, option for 60,900 shares, and 10,200 RSUs.
- Richman entitled to $27,200/month consulting fee for 12 months, plus 329,400 option and 54,900 RSUs vesting on first anniversary.
- Board adopted new non-employee director compensation policy: annual cash retainers ($40k board, $7.5k audit, etc.) plus initial option of 21,000 shares and annual award of 10,500 shares.
- One-time off-cycle annual option of 10,500 shares granted to each non-employee director on Sept 20, 2022, vesting before next annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/0001104659-22-101644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000110465922101644/tm2226134d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-101644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer